COST ASSOCIATED WITH SELF-EXPANDABLE VALVES IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT IN LATIN AMERICA
Author(s)
Ferreira CN1, Okumura LM2, Riveros BS3, Lucchetta RC3, Rosim MP4, Nita ME5
1Edwards Lifesciences Latam, São Paulo, Brazil, 2Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 3Universidade Federal do Paraná, Curitiba, Brazil, 4Universidade de São Paulo, São Paulo, Brazil, 5Market Access and Patient Engagement Solutions - MAPES, São Paulo, Brazil
OBJECTIVES:: to estimate the economic impact of Transcatheter aortic valve replacement in Latin America. METHODS:: To determine the costs and efficacy of each technology Balloon-expandable valve (BEV) and self-expandable valves (SEV), a literature review was performed, aiming to find acquisition costs and probabilities of cardiovascular mortality, myocardial infarction, renal failure, stroke, major vascular complications, and other relevant cardiovascular outcomes. Costs were expressed as USD and five Latin American countries were selected for the base case (Brazil, Mexico, Argentina, Porto Rico and Chile). Time horizon was set at 30 days, based on mortality outcomes reported at clinical trials on valve replacement and other post-commercialization studies. RESULTS:: BEV and SEV were associated with lower rates of mortality (1-4%),. Overall, myocardial infarction, renal failure, stroke, major vascular complications and other outcomes were improved with BEV (Sapien 3®). On average, by considering all countries, the overall cost difference between BEV and other technologies was –5,800 USD/patient. Argentina was the most expensive setting, where the average cost between BEV and other medical devices was USD 9,447 vs 23,319; while the lowest cost was observed in Brazil (USD 2,060 vs 6,767). CONCLUSIONS:: It is recognizable that there are a low number of randomized controlled trials and other primary comparative evidences to estimate comparative value of medical devices, when compared to medications. Therefore, we identified studies comprising patients requiring aortic valve replacement and various TAVI technologies to infer the costs related to each technology. In the aforementioned countries, Sapien 3® might be an efficient technology for aortic valve replacement, in comparison to other technologies.
Conference/Value in Health Info
2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PMD21
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders